Advertisement
Advertisement
U.S. markets close in 4 hours 56 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Calliditas Therapeutics AB (publ) (CALT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.51+1.18 (+5.51%)
As of 11:04AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close21.33
Open22.25
Bid22.33 x 1200
Ask22.51 x 800
Day's Range22.25 - 22.51
52 Week Range12.55 - 32.92
Volume2,751
Avg. Volume7,293
Market Cap665.819M
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est61.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CALT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Calliditas Therapeutics AB
    Daily – Vickers Top Buyers & Sellers for 12/08/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    8 months agoArgus Research
View more
  • PR Newswire

    Number of shares and votes in Calliditas Therapeutics

    During July, Calliditas Therapeutics AB (publ) has issued 51,399 ordinary shares as part of the company's long-term incentive program for certain members of the board of directors issued in 2019, Board LTIP 2019, and converted 5,908,018 class C-shares to 5,908,018 ordinary shares as part of the establishment of the company's at-the-market program. Thus, as of July 29, 2022, the number of shares and votes in the company amounts to 59,157,587 shares and 59,157,587 votes.

  • Zacks

    How Much Upside is Left in Calliditas Therapeutics AB Sponsored ADR (CALT)? Wall Street Analysts Think 200%

    The consensus price target hints at a 200.3% upside potential for Calliditas Therapeutics AB Sponsored ADR (CALT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  • PR Newswire

    Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics

    Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), announced today that our partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") has been granted conditional marketing authorization for Kinpeygo® (developed under the name NEFECON) by the European Commission for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram.

Advertisement
Advertisement